Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/10/2001EP1141000A1 Superantigens
10/10/2001EP1140995A2 Peptides for inhibiting hbv core proteins
10/10/2001EP1140989A1 Alpha(v) beta(6) integrin inhibitors
10/10/2001EP1140987A1 Peptides for inhibiting hpv e6 proteins
10/10/2001EP1140984A1 Selective inhibitors of mmp-12
10/10/2001EP1140980A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same
10/10/2001EP1140972A1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
10/10/2001EP1140971A1 Antisense modulation of novel anti-apoptotic bcl-2-related proteins
10/10/2001EP1140970A1 47 human secreted proteins
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140966A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140948A1 Camptothecin analogs and methods of preparation thereof
10/10/2001EP1140944A1 Epothilone derivatives and their use as antitumor agents
10/10/2001EP1140942A2 Prenyl transferase inhibitors
10/10/2001EP1140938A2 High affinity inhibitors for target validation and uses thereof
10/10/2001EP1140936A1 Tricyclic inhibitors of poly(adp-ribose) polymerases
10/10/2001EP1140935A2 1,2-annelated quinoline derivatives
10/10/2001EP1140931A1 5ht1 antagonists for antidepressant therapy
10/10/2001EP1140927A1 1,4-benzodiazepinone derivatives and their use as integrin antagonists
10/10/2001EP1140916A1 Heteroaryl-cyclic acetals
10/10/2001EP1140909A1 Novel inhibitors of farnesyl-protein transferase
10/10/2001EP1140904A1 Farnesyl protein transferase inhibitors
10/10/2001EP1140902A1 Tricyclic farnesyl protein transferase inhibitors
10/10/2001EP1140901A2 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
10/10/2001EP1140900A2 Pyrazole compounds and uses thereof
10/10/2001EP1140896A1 Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
10/10/2001EP1140895A2 Thiopyran compounds as inhibitors of mmp
10/10/2001EP1140889A2 Compounds and methods for modulation of estrogen receptors
10/10/2001EP1140885A1 Method for high yield extraction of paclitaxel from paclitaxel-containing material
10/10/2001EP1140867A1 New beta-amide and beta-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
10/10/2001EP1140860A1 Pyrimidine compounds
10/10/2001EP1140859A2 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
10/10/2001EP1140858A2 Arylpropenylimidazoles as farnesyl-protein transferase inhibitors
10/10/2001EP1140840A1 -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
10/10/2001EP1140823A1 Glucagon antagonists/inverse agonists
10/10/2001EP1140818A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase
10/10/2001EP1140809A1 New biphenyl and biphenyl-analogous compounds as integrin antagonists
10/10/2001EP1140792A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
10/10/2001EP1140786A1 Reductive alkylation of secondary amines with hydrosilane
10/10/2001EP1140784A2 Ion channel modulating agents
10/10/2001EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
10/10/2001EP1140745A1 Colchinol derivatives as vascular damaging agents
10/10/2001EP1140291A1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
10/10/2001EP1140290A2 Synergistic tumorcidal response induced by histamine
10/10/2001EP1140289A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonic energy
10/10/2001EP1140212A2 The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
10/10/2001EP1140208A1 Pharmaceutical compositions comprising immortalised endothelial cells
10/10/2001EP1140204A2 Vitronectin receptor antagonist pharmaceuticals
10/10/2001EP1140202A1 Peptidic product, process and composition
10/10/2001EP1140200A1 Anthraquinone anticancer drugs
10/10/2001EP1140198A1 A composition and method for the enhancement of the efficacy of drugs
10/10/2001EP1140197A1 Soluble compositions of toremifene
10/10/2001EP1140196A1 Soluble compositions of triphenylethylene antiestrogens
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140181A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140176A1 Transcutaneous photodynamic treatment of targeted cells
10/10/2001EP1140175A2 Antibodies to truncated vegf-d and uses thereof
10/10/2001EP1140174A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140170A1 Novel agents and methods for treatment and diagnosis of ocular disorders
10/10/2001EP1140168A1 Use of antibodies for anticancer vaccination
10/10/2001EP1140167A1 Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
10/10/2001EP1140154A2 Chorionic gonadotropin dna vaccines and methods
10/10/2001EP1140149A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
10/10/2001EP1140147A2 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
10/10/2001EP1140141A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells
10/10/2001EP1140138A2 Therapeutic applications of flint polypeptides
10/10/2001EP1140136A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
10/10/2001EP1140133A1 Controlled release formulation comprising gnrh-ii
10/10/2001EP1140130A2 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
10/10/2001EP1140126A1 A nascent gold based herbal composition
10/10/2001EP1140122A1 Pro-apoptotic agents
10/10/2001EP1140120A2 Human brainiac-5
10/10/2001EP1140116A1 Use of adenosine agonists in cancer therapy
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140078A2 Benzimidazole vascular damaging agents
10/10/2001EP1140073A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
10/10/2001EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
10/10/2001EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140064A2 Oral administration of taxoid derivatives
10/10/2001EP1140052A2 Sensitizing agents for the treatment of skin lesions
10/10/2001EP1140048A2 Methods for treating certain diseases using naaladase inhibitors
10/10/2001EP1140047A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
10/10/2001EP1140045A2 Homer a new target of treating psychiatric disorders
10/10/2001EP1140028A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same
10/10/2001EP1140024A2 Particles for oral delivery of peptides and proteins
10/10/2001EP1140022A2 Method of administering a compound to multi-drug resistant cells
10/10/2001EP1140017A1 Water-insoluble drug delivery system
1 ... 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 ... 2211